Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Acute Attack of NMOSD (EASE-NMO)
NCT07184840Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of eculizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Proportion of improvement in Opticospinal Impairment Scale (OSIS) by 2 points or more at 4 weeks. Started Sep 2025; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07184840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184840.